The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease – (Eye Journal AOP)
The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease Eye advance online publication, October 9 2015. doi:10.1038/eye.2015.170 Authors: J Taylor, L J Scott, C A Rogers, A Muldrew, D O’Reilly, S Wordsworth, N Mills, R Hogg,
Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab – (Eye Journal AOP)
Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab Eye advance online publication, October 9 2015. doi:10.1038/eye.2015.175 Authors: T D Papakostas, L Lim, T van Zyl, J B Miller, B S Modjtahedi, C M Andreoli, D Wu, L H Young, I K Kim, D
Nasolacrimal duct intubation in the treatment of congenital nasolacrimal duct obstruction in older children – (Eye Journal AOP)
Nasolacrimal duct intubation in the treatment of congenital nasolacrimal duct obstruction in older children Eye advance online publication, October 9 2015. doi:10.1038/eye.2015.189 Authors: S Okumuş, V Öner, C Durucu, E Coşkun, Ü Aksoy, E Durucu, L Şahin & I Erbağcı
Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ – (Eye Journal AOP)
Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ Eye advance online publication, October 9 2015. doi:10.1038/eye.2015.190 Author: V P Dave
Response to: ‘Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ – (Eye Journal AOP)
Response to: ‘Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ Eye advance online publication, October 9 2015. doi:10.1038/eye.2015.191 Authors: N Homer, D S Grewal, R G Mirza, A T Lyon & M K Gill